Does Rallies show Form 4 insider transactions for RLMD?

Yes. Rallies tracks RLMD insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is RLMD research on Rallies investment advice?

No. Rallies provides research, data, and educational context for RLMD. It does not provide personalized investment advice.

RLMD (Relmada Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Relmada Therapeutics, Inc. Common Stock (RLMD) is a publicly traded Healthcare sector company. As of May 21, 2026, RLMD trades at $7.19 with a market cap of $665.00M and a P/E ratio of -4.83. RLMD moved +1.99% today. Year to date, RLMD is +69.50%; over the trailing twelve months it is +1101.01%. Its 52-week range spans $0.24 to $8.00. Analyst consensus is strong buy with an average price target of $15.00. Rallies surfaces RLMD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading RLMD stock inside the company?

Recent RLMD insider activity includes TRAVERSA SERGIO bought 27.50K, Shenouda Maged bought 11.66K, Shenouda Maged bought 500.00K, Ence Chuck bought 136.00K, and TRAVERSA SERGIO bought 272.50K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

RLMD Key Metrics

Key financial metrics for RLMD
Metric	Value
Price	$7.19
Market Cap	$665.00M
P/E Ratio	-4.83
EPS	$-1.45
Dividend Yield	0.00%
52-Week High	$8.00
52-Week Low	$0.24
Volume	3
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-57.39M
Gross Margin	0.00%

Recent RLMD Insider Trades

TRAVERSA SERGIO bought 27.50K (~$113.30K) on Dec 15, 2025.
Shenouda Maged bought 11.66K (~$48.06K) on Dec 15, 2025.
Shenouda Maged bought 500.00K (~$1.10M) on Nov 5, 2025.
Ence Chuck bought 136.00K (~$299.20K) on Nov 5, 2025.
TRAVERSA SERGIO bought 272.50K (~$599.50K) on Nov 5, 2025.

Latest RLMD News

Relmada Posts $8.5M Q1 Loss, $183M Cash; Launches Phase 3 Depression Trial — May 13, 2026
Relmada to Showcase 12-Month Phase 2 NDV-01 Data and Phase 3 Overview — May 5, 2026
Relmada Reports $19.9M Q4 Loss, Starts Phase III Bladder Trial — Mar 20, 2026
Relmada Therapeutics Achieves 95% CR Rate and Secures $160M PIPE for Phase 3 — Mar 19, 2026
Relmada’s NDV-01 Delivers 92% Response Rate and 61% Stock Surge — Mar 9, 2026

RLMD Analyst Consensus

3 analysts cover RLMD: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $15.00.

Common questions about RLMD

Who is trading RLMD stock inside the company?: Recent RLMD insider activity includes TRAVERSA SERGIO bought 27.50K, Shenouda Maged bought 11.66K, Shenouda Maged bought 500.00K, Ence Chuck bought 136.00K, and TRAVERSA SERGIO bought 272.50K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for RLMD?: Yes. Rallies tracks RLMD insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is RLMD research on Rallies investment advice?: No. Rallies provides research, data, and educational context for RLMD. It does not provide personalized investment advice.